In the realm of diabetes and weight management, medical advancements continue to reshape treatment options, providing new hope for people seeking effective solutions. Among these innovations, tirzepatide stands out as a groundbreaking medication with the potential to revolutionize the way we address these interconnected concerns. At Horizons, we are excited to introduce a new weight loss program that utilizes tirzepatide (also known by the brand name Mounjaro).

What is Tirzepatide?

Tirzepatide belongs to a class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This combination of GIP and GLP-1 agonism sets tirzepatide apart from other medications, offering a unique approach to managing both diabetes and weight.

How does Tirzepatide work?

Tirzepatide’s dual agonism of GIP and GLP-1 receptors allows it to address multiple aspects of diabetes and weight management simultaneously. By activating GIP and GLP-, tirzepatide’s mechanism of action extends beyond glucose regulation. It also targets weight management by acting on the brain’s satiety centers, reducing appetite, and promoting a sense of fullness. By addressing both high blood sugar and excessive food intake, tirzepatide tackles the dual challenges faced by people struggling with weight loss. Tirzepatide is administered once weekly through a subcutaneous injection. Using tirzepatide as part of a weight loss program with Horizons gives you the extra support that is often needed for long term weight loss. 

Horizons is always working to bring you the latest and most effective weight loss treatments, and design our programs with your success in mind. If you’re interested in more information about our tirzepatide program, simply text us at 937-898-4942.